Exploring Biogen's Interest in Viridian Therapeutics and Pharvaris for Acquisition
Tuesday, 16 July 2024, 15:10
Exploring Biogen's M&A Interests
Recent reports suggest that Biogen is eyeing Viridian Therapeutics and Pharvaris for potential mergers and acquisitions. Both companies' stocks experienced significant gains following this speculation.
Rising Stock Prices
Viridian Therapeutics (VRDN) and Pharvaris (PHVS) witnessed an uptrend as analysts identified them as prime targets for Biogen.
- Wedbush Names Top M&A Targets
- Speculation Boosts Stock Performance
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.